In:
Cancer, Wiley, Vol. 119, No. 18 ( 2013-09), p. 3272-3279
Abstract:
In patients who receive treatment for prostate cancer with radiation therapy, the C‐reactive protein (CRP) levels are associated with biochemical failure‐free survival on multivariable analysis. In the postradical prostatectomy setting, CRP is associated with prostate‐specific antigen (PSA) levels in patients who have Gleason scores ≥8, those with pretreatment PSA levels 〉 20 ng/mL, and high‐risk patients. In the setting of treatment with definitive radiation therapy, CRP is associated with PSA for intermediate‐risk and high‐risk patients and for those with pretreatment PSA levels 〉 20 ng/mL.
Type of Medium:
Online Resource
ISSN:
0008-543X
,
1097-0142
DOI:
10.1002/cncr.v119.18
Language:
English
Publisher:
Wiley
Publication Date:
2013
detail.hit.zdb_id:
1479932-7
detail.hit.zdb_id:
2599218-1
detail.hit.zdb_id:
2594979-2
detail.hit.zdb_id:
1429-1
Permalink